Company intelligence / Profile preview

LAPIX Therapeutics

Cambridge/Boston, Massachusetts, United Stateslapix.com ↗

Ownership: Private
Development stage: Phase 1

Overview

LAPIX recently reported positive topline results from a Phase 1 trial of its lead candidate LPX-TI641. The drug was safe and well tolerated at all tested doses with no maximum tolerated dose identified. Notably, it did not induce neutropenia or lymphocytopenia—side effects common to many autoimmune therapies—suggesting a potentially improved safety profile. The company is advancing toward Phase 2 trials.

Therapeutic areas: OncologyImmunology
Modalities: Small molecules (specifically, orally bioavailable small molecule agonists of TIM receptors)
Industry: Biotech

Drug pipeline

5 assets

lpx-ti641

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on LAPIX Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAPIX Therapeutics.

Explore the full profile